[Studies on the antithrombotic effects of anti-platelet mAb SZ-21 F(ab')(2) fragment].
OBJECTIVE
To research the biological effect of the F(ab')(2) of anti-platelet GPIIIa mAb SZ-21.


METHODS
The F(ab')(2) fragment was obtained with papain digestion for 20 hours at 4 degrees Celsius, under acid condition(pH 5.5). The products were purified through DEAE-52 ion exchange column and the first eluted peak components were verified as F(ab')(2) by SDS-PAGE. The immunoactivity and its antithrombotic effects of fragment were detected by ELISA and platelet aggregation inhibition test, respectively.


RESULTS
The recovery rate of the fragment was 60.32%, its immunoactivity was 0.8 x10(-9) mol/L by ELISA. The 50% effective dose (ED(50)) in the platelet aggregate inhibition test was 3.395 mg/L.


CONCLUSIONS
The F(ab')(2) fragment was superior to intact IgG in binding to platelets and inhibiting platelet aggregation. Thus the F(ab')(2) fragment of mAb SZ-21 opens up broad prospects for its application to the clinical antithrombotic therapy.
Shao
Bo-Jing
BJ
Jiangsu Institute of Hematology,The First Affiliated Hospital to Suzhou University, Suzhou 215006, China.
Zhao
Yi-Min
YM
Shen
Fei
F
Ruan
Chang-Geng
CG
D000911:Antibodies, Monoclonal / Q000276:immunology; D001792:Blood Platelets / Q000276:immunology; D004591:Electrophoresis, Polyacrylamide Gel; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000276:immunology; D007074:Immunoglobulin G
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G